REG - GENinCode PLC - CARDIO inCode be presented at conference

GenincodeAnnouncement

22/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230522:nRSV1087Aa&default-theme=true

RNS Number : 1087A  GENinCode PLC  22 May 2023

GENinCode Plc

("GENinCode" or the "Company")

 

CARDIO inCode® study for risk of incident Coronary Heart Disease

to be presented at European Society of Cardiology Annual Meeting in Amsterdam

 

Oxford, UK. GENinCode Plc (AIM: GENI), the genetics company focused on the
prevention of cardiovascular disease, announces the presentation by Kaiser
Permanente, US on the 'Utility of the CARDIO inCode-Score® polygenic risk
score for incident coronary heart disease interplay with lifestyle in a
multi-ethnic cohort of more than 60,000 individuals'. The presentation will be
made at the European Society of Cardiologists Congress on 25-28 August 2023 in
Amsterdam.

 

The study investigated a subset of over 60,000 adult individuals with no
history of Coronary Heart Disease (CHD) from the Genetic Epidemilogy Resource
in Adult Health and Aging (GERA) multi-ethnic cohort of the Kaiser Permanente
Medical Care plan of Northern California, USA. The GERA cohort followed the
membership over an average follow-up of 6.5 years, using CARDIO inCode-Score®
(CIC-SCORE) to assess the polygenic risk of CHD, the interplay with lifestyle
and incidence of CHD. Coronary heart and circulatory disease known
collectively as Cardiovascular disease (CVD) is the leading cause of death
globally, taking an estimated 17.9 million lives each year.

 

GENinCode specialises in polygenic risk assessment of CHD which is the most
common form of heart disease and the leading cause of death in the United
States.

 

CARDIO inCode-Score® or CIC-SCORE is now entering Early Access Programs with
leading US healthcare institutions and has been granted its CPT PLA code from
the American Medical Association for health insurance coverage and
reimbursement. The CPT PLA Code will enable increased access to the CIC-SCORE
test for those patients with clinical risk factors and/or a family history of
risk of CHD.

 

CIC-SCORE is an in-vitro diagnostic test used to assess an individuals genetic
risk of CHD. The test is based on published clinical evidence amassed over 15
years which, combined with traditional clinical risk factors, provides a
comprehensive risk assessment (clinical + genetic) of CHD for use in primary
preventive care. GENinCode labs process patient DNA samples and deliver the
CARDIO inCode-Score® test results to physicians via a online cloud based
algorithmic reporting system ('SITAB').

 

CIC-SCORE also addresses the well-recognised need for improvement in the
cardiovascular disease (CVD) standard of care across ethnicities where
individuals from certain racial and ethnic groups face higher risks of CVD.
The CIC-SCORE test provides an improved estimation of an individual's risk of
heart attack over their lifetime, particularly within a 10-year period post
testing when combined with traditional clinical risk scoring. CIC-SCORE
provides a major step change in patient risk assessment for CVD enabling
improvement in risk assessment, preventive care and personalised treatment
resulting in a lower incidence of major adverse cardiovascular events, such as
heart attack or stroke.

 

In the UK around 7.6m people live with heart and circulatory disease, which
causes 25% of all deaths annually(1). CVD can be reduced by identifying and
treating individuals at risk, and the NHS 10 Year Plan (2019) sets out to
address CVD prevention.

 

Matthew Walls, CEO of GENinCode PLC said: "We are delighted with progress the
Kasier Permanente team have made to complete this milestone study. This
communication represents the first of a series of publications showing the
clinical utility of polygenic risk assessment to identify individuals at high
genetic risk of coronary heart disease, thereby enabling targeted treatment
and a breakthrough in primary preventive care."

 

For more information visit www.genincode.com (http://www.genincode.com)

Enquiries:

 

 GENinCode Plc                          www.genincode.com (http://www.genincode.com) or via Walbrook PR
 Matthew Walls, CEO

 Stifel Nicolaus Europe Limited (Nomad and Joint Broker)                                      Tel: +44 (0)20 7710 7600
 Alex Price / Ben Maddison / Richard Short

 Cenkos Securities Plc (Joint Broker)   Tel: +44 (0)20 7397 8900
 Giles Balleny
 Dale Bellis / Michael Johnson (Sales)

 Walbrook PR Limited                                                Tel: 020 7933 8780 or genincode@walbrookpr.com

 Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage

 

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of
cardiovascular disease. Cardiovascular disease is the leading cause of death
and disability worldwide.

 

GENinCode operates business units in the UK, Europe through GENinCode S.L.U,
and in the United States through GENinCode U.S. Inc.

 

GENinCode predictive technology provides patients and physicians with globally
leading preventative care and treatment strategies. GENinCode CE marked
invitro-diagnostic molecular tests combine clinical algorithms and
bioinformatics to provide advanced patient risk assessment to predict
cardiovascular disease.

 

About Kaiser Permanente:

Founded in 1945, Kaiser Permanente is one of the United States largest
not-for-profit health plans, serving more than 9 million members, with
headquarters in Oakland, California.

It comprises: Kaiser Foundation Hospitals and their subsidiaries Kaiser
Foundation Health Plan, Inc. The Permanente Medical Groups.

Kaiser Permanente physicians are responsible for medical decisions. The
Permanente Medical Groups, which provide care for Kaiser Permanente members,
continuously develop and refine medical practices to help ensure that care is
delivered in the most efficient and effective manner possible.

Kaiser Permanente's creation resulted from the challenge of providing
Americans medical care during the Great Depression and World War II, when most
people could not afford to go to a doctor. Among the innovations it has
brought to U.S. health care are:

·    Prepaid health plans, which spread the cost to make it more
affordable

·    Physician group practice to maximize their abilities to care for
patients

·    A focus on preventing illness as much as on caring for the sick

·    An organized delivery system, putting as many services as possible
under one roof.

About Cardiovascular Disease (CVD):

Heart and circulatory disease known collectively as Cardiovascular disease
(CVD) are the leading cause of death globally, taking an estimated 17.9
million lives each year. CVD is a group of disorders of the heart and blood
vessels that include coronary heart disease, cerebrovascular disease,
rheumatic heart disease and other conditions. More than four out of five CVD
deaths are due to heart attacks and strokes, and one third of these deaths
occur prematurely in people under 70 years of age.

 

Coronary heart disease is the most common type of heart disease. In 2021 in
the US, coronary heart disease accounted for 375,476 deaths. About 1 in 20
adults age 20 and older have CHD (about 5%). In 2021, about 2 in 10 deaths
from CHD happened in adults less than 65 years old. Globally it is estimated
around 200 million people are living with coronary heart disease. Around 110
million men and 80 million women have coronary heart disease. Coronary heart
disease kills an estimated nine million people each year - in 2019 it was the
world's single biggest killer.

 

In the UK, cardiovascular disease causes a quarter of all deaths and is the
largest cause of premature mortality in deprived areas and the single biggest
area where the NHS can save lives over the next 10 years. CVD is largely
preventable, through lifestyle changes and a combination of public health and
NHS action on smoking and tobacco addiction, obesity, tackling alcohol misuse
and food reformulation.

 

Aside from the genetic risk of cardiovascular disease, the most important
behavioural risk factors of heart disease and stroke are unhealthy diet,
physical inactivity, tobacco use and harmful use of alcohol. The effects of
behavioural risk factors may show up in individuals as raised blood pressure,
raised blood glucose, raised blood lipids,  excess weight and obesity. These
"clinical risks factors" can be measured in primary care facilities and
indicate an increased risk of heart attack, stroke, heart failure and other
complications.

 

Identifying those at highest risk of coronary heart disease and ensuring they
receive appropriate treatment can prevent premature deaths. Access to
medicines and basic health technology in all primary health care facilities is
essential to ensure that those in need receive treatment and counselling.

 

Early detection and treatment of CVD can help patients live longer, healthier
lives is set out in the NHS 10 Year Plan. Too many people are still living
with undetected, high-risk conditions such as raised cholesterol, high blood
pressure and atrial fibrillation (AF). Globally, healthcare systems are making
progress on identification and diagnosis of high genetic risk individuals and
working towards people routinely knowing and understanding their 'ABC' (AF,
Blood pressure and Cholesterol risk). Replicating this approach is now
increasingly possible with advanced molecular testing and digital technology.

 

1.
https://www.bhf.org.uk/-/media/files/for-professionals/research/heart-statistics/bhf-cvd-statistics-uk-factsheet.pdf?rev=e771367bf0654a4dae85cbc9dbefae17&hash=76C0182379BB6EE118EC6F76FA35A158#:~:text=There%20are%20around%207.6%20million,these%20numbers%20rise%20still%20further
(https://www.bhf.org.uk/-/media/files/for-professionals/research/heart-statistics/bhf-cvd-statistics-uk-factsheet.pdf?rev=e771367bf0654a4dae85cbc9dbefae17&hash=76C0182379BB6EE118EC6F76FA35A158#:~:text=There%20are%20around%207.6%20million,these%20numbers%20rise%20still%20further)
.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSEMESSEDSESI